用于美国食品药品监督管理局批准高风险医疗器械补充申请的临床研究特征
该描述性研究分析了2006年4月19日至2015年10月9日期间支持美国食品药品监督管理局(FDA)批准panel-track补充申请的83项临床研究,发现仅45%为随机对照试验、30%为盲法研究,81%的主要终点为替代终点,多数研究样本量有限且随访时间较短。作者认为支持高风险医疗器械修改批准的研究和数据质量应予以改善。
要点
- 83项研究支持78项panel-track补充申请,其中71项(91%)仅由单项研究支持。
- 仅37项(45%)为随机对照试验,25项(30%)为盲法研究,81%的主要终点为替代终点。
- 33项研究(40%)未报告所有入组患者的年龄,25项(30%)未报告性别。
核心结论
- 在用于支持FDA批准高风险医疗器械修改的临床研究中,不足一半为随机、盲法或对照设计,且多数主要终点基于替代终点。
- 这些发现提示,用于支持FDA批准高风险医疗器械修改的研究和数据质量应予以改善。
研究设计与样本
- 描述性研究,分析2006年4月19日至2015年10月9日期间获FDA批准的panel-track补充申请所依据的临床研究。
主要发现
- 83项临床研究支持78项panel-track补充申请,其中71项(91%)补充申请仅由单项研究支持。
- 83项研究中,37项(45%)为随机对照试验,25项(30%)为盲法研究。
- 每项研究中位患者数为185例(四分位距75-305例),中位随访时间为180天(四分位距84-270天)。
- 共150个主要终点(每项研究均值[标准差]1.8[1.2]个),其中57个(38%)与对照比较;有对照的主要终点中,6个(11%)为回顾性对照,51个(89%)为活性对照。
- 121个主要终点(81%)为替代终点;33项研究(40%)未报告所有入组患者的年龄,25项(30%)未报告性别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-risk medical devices often undergo modifications, which are approved by the US Food and Drug Administration (FDA) through various kinds of premarket approval (PMA) supplements. There have been multiple high-profile recalls of devices approved as PMA supplements. OBJECTIVE: To characterize the quality of the clinical studies and data (strength of evidence) used to support FDA approval of panel-track supplements (a type of PMA supplement pathway that is used for significant changes in a device or indication for use and always requires clinical data). DESIGN AND SETTING: Descriptive study of clinical studies supporting panel-track supplements approved by the FDA between April 19, 2006, and October 9, 2015. EXPOSURE: Panel-track supplement approval. MAIN OUTCOMES AND MEASURES: Methodological quality of studies including randomization, blinding, type of controls, clinical vs surrogate primary end points, use of post hoc analyses, and reporting of age and sex. RESULTS: Eighty-three clinical studies supported the approval of 78 panel-track supplements, with 71 panel-track supplements (91%) supported by a single study. Of the 83 studies, 37 (45%) were randomized clinical trials and 25 (30%) were blinded. The median number of patients per study was 185 (interquartile range, 75-305), and the median follow-up duration was 180 days (interquartile range, 84-270 days). There were a total of 150 primary end points (mean [SD], 1.8 [1.2] per study), and 57 primary end points (38%) were compared with controls. Of primary end points with controls, 6 (11%) were retrospective controls and 51 (89%) were active controls. One hundred twenty-one primary end points (81%) were surrogate end points. Thirty-three studies (40%) did not report age and 25 (30%) did not report sex for all enrolled patients. The FDA required postapproval studies for 29 of 78 (37%) panel-track supplements. CONCLUSIONS AND RELEVANCE: Among clinical studies used to support FDA approval of high-risk medical device modifications, fewer than half were randomized, blinded, or controlled, and most primary outcomes were based on surrogate end points. These findings suggest that the quality of studies and data evaluated to support approval by the FDA of modifications of high-risk devices should be improved.
引用
- Zheng SY, Dhruva SS, Redberg RF, et al. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements. JAMA. 2017. PMID: 28810022. doi:10.1001/jama.2017.9414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。